期刊
JOURNAL OF DIABETES RESEARCH
卷 2015, 期 -, 页码 -出版社
HINDAWI LTD
DOI: 10.1155/2015/706416
关键词
-
资金
- Eli Lilly Japan
- Novo Nordisk Inc.
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
- GlaxoSmithKline
- Takeda Pharmaceutical Company Limited
- Daiichi-Sankyo Co., Ltd.
- Taisho Pharmaceutical Co., Ltd.
- Astellas Pharma US, Inc.
- AstraZeneca Pharmaceuticals LP
Aims. Glucagon-like peptide-1 (GLP-1) analog promotes insulin secretion by acting on pancreatic beta-cells. This antihyperglycemic treatment for type 2 diabetes mellitus (DM) has attracted increased clinical attention not only for its antihyperglycemic action but also for its potential extrapancreatic effects. We investigated whether liraglutide, a GLP-1 analog, could enhance insulin sensitivity as assessed by the hyperinsulinemic-euglycemic clamp in type 2 DM patients. Materials. We prospectively enrolled 31 uncontrolled type 2 DM patients who were hospitalized and equally managed by guided diet-and exercise-therapies and then introduced to either liraglutide- or intensive insulin-therapy for 4 weeks. Insulin sensitivity was assessed by the glucose infusion rate (GIR) using hyperinsulinemic-euglycemic clamp before and after the therapies. Results. Values of HbA1c, postprandial plasma glucose, and body mass index (BMI) were significantly decreased by hospitalized intensive insulin-therapy or liraglutide-therapy. GIR was significantly increased by liraglutide-therapy but not by insulin-therapy, indicating that liraglutide-therapy significantly enhanced insulin sensitivity. BMI decreased during liraglutide-therapy but was not significantly correlated with changes in GIR. Multivariate logistic regression analysis demonstrated that liraglutide-therapy significantly correlated with increased insulin sensitivity in uncontrolled DMpatients. Conclusions. Liraglutide may exhibit favorable effects on diabetes control for type 2 DMpatients by increasing insulin sensitivity as an extrapancreatic action.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据